Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Keros Therapeutics (KROS)
NASDAQ:KROS
Keros Therapeutics (KROS) Stock Price & Analysis
184 Followers
KROS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$27.02 - $73.00
Previous Close$60.57
Volume572.09K
Average Volume (3M)364.40K
Market Cap
$2.18B
Enterprise Value$1.91B
Total Cash (Recent Filing)$287.90M
Total Debt (Recent Filing)$14.31M
Price to Earnings (P/E)-11.7
Beta1.06
Next Earnings
Aug 01, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.19
Shares Outstanding35,982,628
10 Day Avg. Volume341,838
30 Day Avg. Volume364,402
Standard Deviation0.21
R-Squared0.10
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)6.18
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-20.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue238.24K
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-13.59
Forecast
1Y Price Target
$94.00Price Target Upside55.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Keros Therapeutics News
PremiumCompany Announcements
Keros Therapeutics Updates Corporate Presentation Online
PremiumCompany Announcements
Keros Therapeutics CMO Simon Cooper Resigns
PremiumCompany Announcements
Keros Therapeutics CEO to Speak at Global Biopharma ConferenceBulls Say, Bears Say
Bulls Say
Clinical Trial ProgressKeros Therapeutics is advancing KER-065 in a Phase 1 trial for obesity, showcasing commitment to addressing this challenging health condition.
Drug ApprovalWinrevair was approved by the FDA for the treatment of pulmonary arterial hypertension (PAH) with a broad indicated patient population.
Regulatory MilestoneThe FDA Advisory Committee's supportive vote for imetelstat highlights its potential as a beneficial treatment for low-risk myelodysplastic syndrome.
Bears Say
Drug EfficacySubgroup analyses suggest limited effect of Winrevair in patients with connective tissue disease, a significant portion of the PAH patient population.
Drug SafetyThe label includes warnings for Winrevair related to erythrocytosis, hemoglobin increases, and severe thrombocytopenia, requiring monitoring.
Regulatory ConcernsSotatercept's dose-dependent effects on hemoglobin and vascular adverse events could necessitate a REMS, highlighting potential safety risks.
---
Ownership Overview
30.27% Insiders
23.05% Mutual Funds
12.71% Other Institutional Investors
33.98% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KROS FAQ
What was Keros Therapeutics’s price range in the past 12 months?
Keros Therapeutics lowest stock price was $27.02 and its highest was $73.00 in the past 12 months.
What is Keros Therapeutics’s market cap?
Currently, no data Available
When is Keros Therapeutics’s upcoming earnings report date?
Keros Therapeutics’s upcoming earnings report date is Aug 01, 2024 which is in 85 days.
How were Keros Therapeutics’s earnings last quarter?
Keros Therapeutics released its earnings results on May 02, 2024. The company reported -$1.3 earnings per share for the quarter, beating the consensus estimate of -$1.333 by $0.033.
Is Keros Therapeutics overvalued?
According to Wall Street analysts Keros Therapeutics’s price is currently Undervalued.
Does Keros Therapeutics pay dividends?
Keros Therapeutics does not currently pay dividends.
What is Keros Therapeutics’s EPS estimate?
Keros Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Keros Therapeutics have?
Keros Therapeutics has 35,982,628 shares outstanding.
What happened to Keros Therapeutics’s price movement after its last earnings report?
Keros Therapeutics reported an EPS of -$1.3 in its last earnings report, beating expectations of -$1.333. Following the earnings report the stock price went down -1.074%.
Which hedge fund is a major shareholder of Keros Therapeutics?
Among the largest hedge funds holding Keros Therapeutics’s share is Woodline Partners LP. It holds Keros Therapeutics’s shares valued at 23M.
---
Keros Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$94.00 (55.19% Upside)
$94.00 (55.19% Upside)
Blogger Sentiment
Bullish
KROS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 85.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 5.0%
Last 30 Days ▼ 5.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
33.73%
12-Months-Change
Fundamentals
Return on Equity
-50.19%
Trailing 12-Months
Asset Growth
20.62%
Trailing 12-Months
Company Description
Keros Therapeutics
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
---
KROS Stock 12 Months Forecast
Average Price Target
$94.00
▲(55.19% Upside)
Technical Analysis
Best Analysts Covering KROS
1 Year
1 Year Success Rate
8/12 ratings generated profit
1 Year Average Return
+30.30%
reiterated a buy rating 2 months ago
Copying Julian Harrison's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +30.30% per trade.
---